



hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: August 28, 2001

By:

*Jennifer Malony*

TECH CENTER 1600/2900  
TECH CENTER 1600/2900  
RECEIVED  
SEP 04 2001  
7/15/01

Attorney Docket No.: 5325-0161.30  
Applicant: Gabizon, et al.  
Serial No.: 09/467,413  
Filing Date: December 17, 1999  
For: **METHOD OF ADMINISTERING A COMPOUND  
TO MULTI-DRUG RESISTANT CELLS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

1. Transmitted herewith are the following:
  - An Amendment Under 37 CFR §1.111
  - A Petition for 2-Month Extension of Time (in triplicate)
2. Entity Status
  - Small Entity Status (37 CFR §1.9 and §1.27) has been established by a previously submitted Small Entity Statement.
3. Conditional Petition for Extension of Time:  
An Extension of Time is requested to provide for timely filing if necessary for timely filing of this transmittal and enclosures.
4. Provisional Fee Authorization  
Please charge any underpayment in fees for timely filing of this transmittal and enclosures to Deposit Account No. 50-0665.

Respectfully submitted,

*Judy M*

Judy M. Mohr  
Registration No. 38,563

Correspondence Address:

Customer No. 22918  
Phone: (650) 838-4300



4.11  
8/30  
SEP 04 2001  
RECEIVED  
TECH CENTER 1600  
PATENT

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: August 28, 2001

By: John J. McHenry

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Gabizon, et al.

SERIAL NO.: 09/467,413

FILED: December 17, 1999

FOR: METHOD OF ADMINISTERING A  
COMPOUND TO MULTI-DRUG RESISTANT  
CELLS

EXAMINER: G. Kishore

ART UNIT: 1615

Amendment Under 37 C.F.R. §1.111

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office action dated March 28, 2001 in the above-identified application, please amend the above-identified application as follows.

In the Specification: On page 2, replace the paragraph starting on line 30 with the following:

A \ Cancers which express P-glycoprotein include cancers derived from tissues which normally express the *MDR1* gene, namely cancers of the liver, colon, kidney, pancreas and adrenal. Expression of the gene is also seen during the course of chemotherapy with multidrug-resistant drugs in leukemias, lymphomas, breast and ovarian cancer, and many other cancers. These cancers initially respond to chemotherapy, but when the cancer relapses, the cancer cells frequently express more P-glycoprotein. There are cancers